Teus Guezala, Miguel A.Arranz Márquez, Esther2016-07-132016-07-132008Teus, M. A., & Arranz-Márquez, E. (2008). Prostaglandin F2α analogues in glaucoma management. Expert Review of Ophthalmology, 3(2), 203-209.17469899http://hdl.handle.net/11268/5407Prostaglandin F2α analogues are the most recent class of ocular hypotensive drugs that have become available for clinical use in patients with glaucoma. The terms `prostanoids' and `prostaglandin analogues' have been used to identify a group of compounds that are structural analogues of naturally occurring prostaglandin F2α; however, each drug has a different molecular structure that confers slightly different properties. The introduction of this group of antiglaucomatous drugs represented a revolution in glaucoma treatment not only as a result of their novel mechanism of action, but also due to the potent ocular hypotensive effect. Most prostaglandin F2α analogues are considered to be a first-line treatment for glaucoma. Although prostaglandin F2α analogues have a low incidence of systemic side effects (in contrast to those reported for other antiglaucomatous medications), their use has been associated with local adverse effects, including a novel intriguing side effect: prostaglandin-induced increased iridial pigmentation.engjournal article10.1586/17469899.3.2.203restricted accessGlaucomaOftalmología